Editorial
Metabolic effects of sacubitril/valsartan: are they relevant in clinical practice?
Abstract
The burden of cardiometabolic diseases continues to rise worldwide (1). Obesity, insulin resistance, atherogenic dyslipidemia, hypertension and intra-abdominal adiposity are strongly interrelated and are crucial determinants of heart failure (HF) (2).
